PATENT COOPERATION TREATY

2458-4042 PC

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION CONCERNING SUBMISSION OR TRANSMITTAL OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

100 NOV -3 A IO: 33

MOROZ, Eugene Morgan & Finnegan L.E.P. 345 Park Avenue New York, NY 10154 ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 23 October 2000 (23.10.00)	
Applicant's or agent's file reference 2458-4042PC	IMPORTANT NOTIFICATION
International application No. PCT/US00/17540	International filing date (day/month/year) 26 June 2000 (26.06.00)
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 25 June 1999 (25.06.99)
Applicant GENAISSANCE PHARMACEUTICALS, INC	C et al

- 1. The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- 2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.
- 3. An asterisk(*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, the attention f the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- 4. The letters "NR" appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date Priority application No.

Country or regional Office or PCT receiving Office

Date of receipt of priority document

25 June 1999 (25.06.99)

60/141,521

US

07 Augu 2000 (07.08.00)

The International Bureau f WIPO 34, chemin des Colombettes 1211 G neva 20, Switzerland **Authorized officer**

Magda BOUACHA

Telephone No. (41-22) 338.83.38

30-10 city

Facsimile No. (41-22) 740.14.35

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TRE

(19) W rld Intellectual Property Organization International Bureau



(43) International Publication Date 4 January 2001 (04.01.2001)

(10) International Publication Number WO 01/01218 A3

(51) International Patent Classification7: 17/00, G01N 33/48, 33/50, G06T 1/00 G06F 7/00,

Andreas, K. [DE/US]; 91 Center Road, Woodbridge, CT 06524 (US). XU, Chuanbo [CN/US]; 524 Openint Hill

(21) International Application Number: PCT/US00/17540

(22) International Filing Date:

26 June 2000 (26.06.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/141,521

25 June 1999 (25.06.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

60/141,521 (CIP)

Filed on

25 June 1999 (25.06.1999)

(71) Applicant (for all designated States except US): GENAIS-SANCE PHARMACEUTICALS, INC. [US/US]; Five Science Park, New Haven, CT 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DENTON, Richard, Rex [US/US]; 129 Hunters Trail, Madison, CT 06443 (US). JUDSON, Richard, S. [US/US]; 42 Baker Hill Drive, Guilford, CT 06437 (US). RUAÑO, Gualberto [US/US]; 88 Lawrence Street, New Haven, CT 06511 (US). STEPHENS, Joel, Claiborne [US/US]; 46 Crabapple Lane, Guilford, CT 06437 (US). WINDEMUTH, Road, Madison, CT 06443 (US).

(74) Agents: MOROZ, Eugene et al.; Morgan & Finnegan,

- L.L.P., 345 Park Avenue, New York, NY 10154 (US). (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
- DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR. HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

With international search report.

(88) Date of publication of the international search rep rt: 7 June 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR OBTAINING AND USING HAPLOTYPE DATA

(57) Abstract: Methods, computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of haplotypes in the general population; methods, program, and database to find correlation's between an individual's haplotypes or genotypes and a clinical outcome; methods, program, and database to predict an individual's haplotypes from the individual's genotype for a gene; and methods, program, and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.

÷		• . • .
		:
•	·	

International application No. PCT/US00/17540

1:1

į

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

DIALOG (files 5, 155) and EAST (files U.S. Patents, European abstracts, Japanese abstracts, and Derwent) search terms: pharmacogenomic, pharmacogenetic, haplotype, genotype, database, computer, clinical trial, population genetics, polymorphism, SNP, Hardy-Weinberg, Mendelian, linkage, phylogenetic, pedigree, locus, gene, phased, unphased

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s)1-8, 69-72, and 120-124, drawn to a method of generating a haplotype database, computer-usable medium, and computer programmed therefore.

Group II, claim(s) 9-12 and 75, drawn to a method of predicting the presence of a haplotype and computer-usable medium therefore.

Group III, claim(s) 13-21, 74-78, and 125-129, drawn to a method of identifying correlation between haplotype pair and clinical response, computer-usable medium, and computer programmed therefore.

Group IV, claim(s) 22-29, 79-82, 150-155, drawn to a method for determining susceptibility to a condition/disease, computer-usable medium, and computer programmed therefore.

Group V, claim(s) 50-35, 85-84, and 154-155, drawn to a method for predicting response to treatment, computer-usable medium, and computer programmed therefore.

Group VI, claim(s) 34, 85, and 186, drawn to a method for generating a tree structure, computer-usable medium, and computer programmed therefore.

Group VII, claim(s) 35, 86, and 137, drawn to a method for displaying haplotype pair frequency, computer-usable medium, and computer programmed therefore.

Group VIII, claim(s) 56-37, 87-88, and 138-139, drawn to a method for displaying a linkage screen, computer-usable medium, and computer programmed therefore.

Group IX, claim(s) 58-40, 89-61, and 140-142, drawn to a method for displaying a phylogenetic tree screen, computerusable medium, and computer programmed therefore.

Group X, claim(s) 41-42, 92-93, and 143-144, drawn to a method for displaying genotypic analysis, computer-usable medium, and computer programmed therefore.

Group XI, claim(s) 45-51, 94-102, and 145-153, drawn to a method to displaying clinical response values, computerusable medium, and computer programmed therefore.

Group XII, claim(s) 52, 103, and 154, drawn to a method for carrying out a genetic algorithm, computer-usable medium, and computer programmed therefore.

Group XIII, claim(s) 55, 104, and 155, drawn to a method for displaying correlations, computer-usable medium, and computer programmed therefore.

Group XIV, claim(s) 54-55, 105-106, and 156-157, drawn to a method for conducting a clinical trial, computer-usable medium, and computer programmed therefore.

Group XV, claim(s) 56-58, 107-109, and 158-160, drawn to a method for inferring genotype, computer-usable medium, and computer programmed therefore.

Group XVI, claim(s) 59-68, 110-119, and 161-170, drawn to a method of determining polymorphic sites or subhaplotypes, computer-usable medium, and computer programmed therefore.

Group XVII, claim(s) 171-175 and 185, drawn to a data structure.

Group XVIII, claim(s) 176-182, drawn to a method for storing and organizing biological information.

The inventions listed as Groups I-XVIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature of each method is the starting materials, method steps, and goal of each method. The corresponding computer-usable medium and computer programmed therefore form part of the inventive concept with each method. Note that PCT Rule 13 does not provide for multiple methods or products.

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)			
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:			
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:			
S. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)			
This International Searching Authority found multiple inventions in this international application, as follows:			
Please See Extra Sheet.			
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.			
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.			
3. X As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 1-21,30-33,35,43-51,53-58,69-78,83-84,86,94-102,104-109,120-129,134-135,137,145-153,155-160,171-185			
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:			
Remark on Protest X The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.			

C (Continua	C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document, with indication, where appropriate, of the relevant	passages Relevant to claim No			
Y	CLARK et al. Haplotype Structure and Population Genet Inferences from Nucleotide-Sequence Variation in Human Lipoprotein Lipase. American Journal of Human Geneti Vol. 63, pages 595-912, see entire document.	51,53-58,69-78,83-			
Y	CASHMAN et al. The Irish cystic fibrosis database. Journ Medical Genetics. 1995, Vol. 32, No. 12, pages 972-975, see document.				
Y, P	TISHKOFF et al. The Accuracy of Statistical Methods in Estimation of Haplotype Frequencies: An Example from the Locus. American Journal of Human Genetics. August 200 67, No. 2, pages 518-522, see entire document.	the CD4 51,53-5869-78, 83-			
Y	PERLIN et al. Toward Fully Automated Genotyping: Alla Assignment, Pedigree Construction, Phase Determination, Recombination Detection in Duchenne Muscular Dystroph American Journal of Human Genetics. 1994, Vol. 55, No. 4777-787, see entire document.	and 51,53-58,69-78,83- ny. 84,86,94-102,104-			
Y	HOANG et al. PAH Mutation Analysis Consortium Data Database for Disease-producing and Other Allelic Variation Human PAH Locus. Nucleic Acids Research. 1996, Vol. pages 127-131, see entire document.	on at the 51,53-58,69-78,83-			
Y, P	STEPHENS et al. Single-nucleotide Polymorphisms, Hap and Their Relevance to Pharmacogenetics. Molecular Dia December 1999, Vol. 4, No. 4, pages 309-317, see entire do	gnosis. 51,53-58,69-78,83-			

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevan	nt passages Relevant to claim No		
Y	KLEYN et al. Genetic Variation as a Guide to Drug De Science. 18 September 1998, Vol. 281, pages 1820-1821, se document.			
Y	MORI et al. HLA Gene and Haplotype Frequencies in t American Population. Transplantation. 15 October 1997, No. 7, pages 1017-1027, see entire document.			
Y	MORI et al. Computer program to predict likelihood of f HLA-matched donor: Methodology, validation, and appli Biology of Blood and Marrow Transplantation. October 2, pages 134-144, see entire document.	cation. 51,53-58,69-78,83-		
Y	MATISE, T. C. Genome Scanning for Complex Disease Using the Transmission/Disequilibrium Test and Haploty Haplotype Relative Risk. Genetic Epidemiology. 1995, No. 6, pages 641-645, see entire document.	pe-based 51,53-58,69-78,83-		
Y	COOPER et al. Network Analysis of Human Y Microsat Haplotypes. Human Molecular Genetics. 1996, Vol. 5, 1 pages 1759-1766, see entire document.			
Y	GENE et al. Haplotype frequencies of eight Y-chromosoloci in Barcelona (North-East Spain). International Jou Legal Medicine. 1999, Vol. 112, pages 403-405, see entire	rnal of 51,53-58,69-78,83-		

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
¥	US 5,773,220 A (DEKOSKY ET AL) 30 June 1998 (30-06-98), see in particular abstract and claims.	1-21,30-33,35,43- 51,53-58,69-78,83- 84,86,94-102,104- 109,120-129,134- 135,137,145-15 3,155-160,171-183		
Y,P	US 5,972,614 A (RUANO ET AL) 26 October 1999 (26-10-99), see in particular abstract; claims; column 6, lines 33-55; column 12, lines 10-25.	1-21,30-33,35,43-51,53-58,69-78,83-84,86,94-102,104-109,120-129,134-135,137,145-153,155-160, 171-183		
Y, P	US 6,022,683 A (POIRIER) 08 February 2000 (08-02-00), see in particular abstract and claims.	1-21,30-33,35,43-51,53-58,69-78,83-84,86,94-102,104-109,120-129,134-135,137,145-153,155-160, 171-183		
Y, P	US 6,043,040 A (ACTON) 28 March 2000 (28-03-00), see in particular abstract, claims, and columns 49-59.	1-21,30-33,35,43- 51,53-58,69-78,83- 84,86,94-102,104- 109,120-129,134- 135, 137,145- 153,155-160,171- 183		
Y	US 5,648,482 A (MEYER) 15 July 1997 (15-07-97), see in particular abstract, claims, and columns 23-26.	1-21,30-33,35,43-51,53-58,69-78,8384,86,94-102,104-109,120-129,134-135,137,145-153,155-160,171-183		
Y, P	US 6,030,778 A (ACTON ET AL) 29 February 2000 (29-02-00), see in particular abstract, claims, and columns 25-30.	1-21,30-33, 35,43- 51,53-58,69-78,83- 84,86,94-102,104- 109,120-129,134- 135,137,145- 153,155-160,171- 183		

A. CLASSIFICATI N F SUBJECT MATTER	·		
IPC(7) :Goef 7/00, 17/00; Go1N 55/48, 55/50; GoeT 1/00 US CL :545/418, 961; 702/18, 20; 707/100, 102, 104			
US CL. :345/418, 961; 702/18, 20; 707/100, 102, 104 According to International Patent Classification (IPC) or to both national classification and IPC			
B. FIELDS SEARCHED			
Minimum documentation searched (classification system followed by c	assification symbols)		
U.S. : 345/418, 961; 702/19, 20; 707/100, 102, 104			
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched			
Electronic data base consulted during the international search (name o	f data base and, where practicable, search terms used)		
Please See Extra Sheet.			
C. DOCUMENTS CONSIDERED TO BE RELEVANT			
Category Citation of document, with indication, where appropri	ate, of the relevant passages Relevant to claim No.		
Y US 5,874,256 A (BERTINA ET AL) 23 February see in particular abstract and claims.	oruary 1999 (23-02-99), 1-21,30-33, 35,43-51,53-58,69-78,83-84,86,94-102,104-109,120-129,134-135,137,145-153,155-160,171-183		
X Further documents are listed in the continuation of Box C.	See patent family annex.		
Special estegories of cited documents: T	later document published after the international filing date or priority		
"A" document defining the general state of the art which is not considered	date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
to be of particular selevance "E" earlier document published on or after the international filing date	document of particular relevance; the claimed invention cannot be		
"I." document which may throw doubts on priority claim(s) or which is crited to establish the wallestion date of another critation or other	considered novel or cannot be considered to involve an inventive step when the document is taken alone		
special reason (as specified) "I" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined "O" document referring to an oral disclosure, no, exhibition or other with one or more other much documents, such combination being			
"P" document published prior to the international filing date but later "ge	obvious to a person skilled in the art document member of the same patent family		
Date of the actual completion of the international search Date	of mailing of the international search report		
14 NOVEMBER 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Pacsimile No. (705) 505-5250 Telephone No. (705) 508-0196			